1. Home
  2. Live Updates
  3. Karyopharm therapeutics

Live Breaking News & Updates on Karyopharm therapeutics

Stay informed with the latest breaking news from Karyopharm therapeutics on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Karyopharm therapeutics and stay connected to the pulse of your community

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $5.86 Consensus Target Price from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among […]

Canada , Piper-sandler , Selective-inhibitor-of-nuclear-export , Karyopharm-therapeutics-inc , Prelude-capital-management , Mercer-global-advisors-inc , Advisor-group-holdings-inc , Nasdaq , Virtu-financial , Royal-bank , Karyopharm-therapeutics-company-profile , Karyopharm-therapeutics

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price […]

Canada , Piper-sandler , Bleakley-financial-group , Advisor-group-holdings-inc , Nasdaq , Prelude-capital-management , Karyopharm-therapeutics-inc , Selective-inhibitor-of-nuclear-export , Royal-bank , Simplicity-solutions , Karyopharm-therapeutics-company-profile , Karyopharm-therapeutics

Antengene Announces Inclusion of XPOVIO (selinexor) in 2023 China's National Reimbursement Drug List

Antengene Announces Inclusion of XPOVIO (selinexor) in 2023 China's National Reimbursement Drug List
philippinetimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from philippinetimes.com Daily Mail and Mail on Sunday newspapers.

Singapore , China , Macau , Australia , Taiwan , South-korea , Shanghai , Hong-kong , Jay-mei , Asia-pacific , Peter-qian , Hong-kong-stock-exchange

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Australia , Hong-kong , China , Macau , South-korea , Shanghai , Taiwan , Singapore , Asia-pacific , Jay-mei , Peter-qian , Karyopharm-therapeutics-inc

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)

Biomarker Data from Phase 1 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis (MF) Suggestive of Disease Modification

Australia , Germany , China , Austria , Boston , Massachusetts , United-states , Canada , Israel , United-kingdom , Singapore , Hong-kong

Community Oncology Pharmacists Should Learn How to Manage Adverse Events Related to New Therapies for Acute Myeloid Leukemia

The pharmacist can help patients to manage symptoms throughout the entire treatment journey.

San-diego , California , United-states , Fort-myers , Florida , American , Natasha-khrystolubova , American-society-of-hematology , Pharmacy-clinical-services , Genentech , Florida-cancer-specialists , Research-institute

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Macau , Taiwan , Shanghai , China , Australia , Hong-kong , Singapore , South-korea , Chinese , Peter-qian , Asia-pacific , Jay-mei

Florida Cancer Specialist Optimizing Use of Anticancer Drugs to Improve Care for Patients with Blood Disorders

A best practice clinical program developed by Florida Cancer Specialists & Research Institute, LLC is ensuring that patients with certain blood disorders achieve maximum clinical benefits from the use of oral medications.

Florida , United-states , New-york , Lucion-gordan , Shachar-peles , Matthew-fink , David-wenk , Myeloma-congress , Karyopharm-therapeutics-inc , Practices-program-in-patients , World-evidence-department , Florida-cancer-specialists-research-institute

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., Dec. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an...

China , United-kingdom , Linkedin , Prnewswire-karyopharm-therapeutics-inc , Karyopharm-therapeutics-inc , Selective-inhibitor-of-nuclear-export , Nasdaq , Stock-incentive-plan , Nasdaq-listing-rule , Selective-inhibitor , Nuclear-export

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price […]

Canada , Piper-sandler , Gareng-bohlin , Victory-capital-management-inc , Bleakley-financial-group , Prelude-capital-management , Karyopharm-therapeutics-company-profile , Karyopharm-therapeutics-inc , Selective-inhibitor-of-nuclear-export , Advisor-group-holdings-inc , Royal-bank , Nasdaq